logo-loader
Advanced Oncotherapy PLC

Schedule 2(g) Disclosure

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";text-transform:uppercase;font-weight:bold;}h2{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:35.45pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:70.9pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h4{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:106.3pt;text-align:justify;text-indent:-35.4pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h5{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:5.0cm;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}h6{margin-top:0cm;margin-right:0cm;margin-bottom:11.0pt;margin-left:177.2pt;text-align:justify;text-indent:-35.45pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:normal;}strong{font-family:"Times New Roman","serif";}em{font-family:"Times New Roman","serif";}p{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";}acronym{font-family:"Times New Roman","serif";} address{margin:0cm;margin-bottom:.0001pt;font-size:10.0pt;font-family:"Times New Roman","serif";font-div:italic;}cite{font-family:"Times New Roman","serif";}code{font-family:Consolas;}dfn{font-family:"Times New Roman","serif";}samp{font-family:Consolas;}tt{font-family:Consolas;}var{font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .mw{size:595.3pt 841.9pt;margin:2.0cm 42.45pt 49.65pt 42.55pt;}div.mw{}p.nt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;font-weight: bold; text-align: center}span.nr{font-size:11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.nu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";color:black;text-align: center}span.np{font-size: 11.0pt;font-family:"Calibri","sans-serif";color:windowtext}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";}span.nn{font-family:"Calibri","sans-serif"}p.nv{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.nw{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align:justify} span.nm{font-family:"Calibri","sans-serif"; color:black}p.nx{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.nk{font-family:"Calibri","sans-serif"; color:#0D0D0D}table.ny{width:489.05pt;margin-left:-12.5pt;border-collapse:collapse}td.nh{width:220.25pt;padding:0cm 5.4pt 0cm 5.4pt}p.nz{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-left: 7.1pt}td.ne{width:247.2pt;padding:0cm 5.4pt 0cm 5.4pt}p.oa{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";text-align: right}span.ng{font-size:10.0pt; font-family:"Calibri","sans-serif"}p.ob{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";margin-left:7.1pt} span.nd{font-family: "Calibri","sans-serif"}p.oc{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}span.od{font-family:"Calibri","sans-serif";color:black}span.oe{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"; color:black}span.of{font-family:"Times New Roman","serif";font-family:"Calibri","sans-serif"}p.og{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify; text-autospace: none}span.na{font-family:"Calibri","sans-serif";color:black}span.oh{font-family:"Times New Roman","serif";font-family: "Calibri","sans-serif"; font-weight: bold} /**/
RNS Number : 5632O
Advanced Oncotherapy PLC
30 January 2019
 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Schedule 2(g) Disclosure

 

Advanced Oncotherapy (AIM: AVO), the developer of a next-generation proton therapy system for cancer treatment, announces the following updates to disclosure in relation to Gabriel Urwitz, Non-Executive Director of the Company, pursuant to AIM Rule 17 and Schedule 2(g)(iii) to (viii) of the AIM Rules.

 

Gabriel Urwitz was a director of Oidun AB from 28 December 2007 to 24 September 2015. The company entered into liquidation on 15 September 2015 and bankruptcy proceedings were filed on 29 September 2015.

 

For further information, please contact:

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 20 3617 8728

Nicolas Serandour, CEO




Stockdale Securities (Nomad & Joint Broker)


Antonio Bossi / David Coaten

Tel: +44 20 7601 6100



Stifel Nicolaus Europe (Joint Broker)


Jonathan Senior

Tel: +44 20 7710 7600



Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or [email protected]

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCLLFSLLSIIVIA

Quick facts: Advanced Oncotherapy PLC

Price: £0.40

Market: LSE
Market Cap: £92.09 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tertiary Minerals, Advanced Oncotherapy among Alan Green's 2018 stocks to watch

Brand Communications' Alan Green highlights his small cap stocks to watch in 2018. First on Alan's hit list is Tertiary Minerals (LON:TYM). Tertiary’s share price has been on a good run recently since it announced they'd signed an MoU with global commodities group Possehl to enter...

on 27/12/17

RNS

Second Price Monitoring Extn

2 weeks, 1 day ago

Price Monitoring Extension

2 weeks, 1 day ago

Result of AGM

3 weeks, 6 days ago

Harley Street update

4 weeks, 2 days ago

Final Results

on 28/6/19